

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**Date of Report: November 16, 2015  
Commission File Number: 001-36891**

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Title</u></b>
99.1	Press release, dated November 16, 2015.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**  
(Registrant)

November 16, 2015

By: /s/ André Choulika  
André Choulika  
Chief Executive Officer

**Collectis Reports Third Quarter and First Nine Months 2015 Financial Results**

NEW YORK--(BUSINESS WIRE)--November 16, 2015--Regulatory News:

Collectis S.A. (Paris:ALCLS) (NASDAQ:CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced its results for the three- and nine-month periods ended September 30, 2015.

**Recent Corporate Highlights****Collectis**

- Completed a series of three production runs of UCART19, its lead TALEN<sup>®</sup> gene edited product candidate, confirming the implementation of Collectis' manufacturing process in GMP conditions.

- Announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will present, during the 2015 American Society of Hematology Annual Meeting (ASH) in December, data from the first in man clinical use of Collectis' TALEN<sup>®</sup> gene edited allogeneic UCART19 product candidate.

- Announced that a poster and an oral presentation on its engineered allogeneic CAR T-cell product candidates, UCARTCS1 and UCART123, will be presented in December during the 2015 American Society of Hematology Annual Meeting (ASH).

**Calyxt**

- Completion of field trials of its non-regulated status cold storable potato product and high oleic soybean product.

**Financial Results**

Since Collectis did not have consolidated financial statements for individual quarters during fiscal year 2014, no comparative quarterly 2014 figures will be presented during 2015. Collectis will publish quarter-over-quarter comparative figures starting with the first quarter of 2016.

Collectis' consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board ("GAAP").

**Third Quarter and First Nine Months 2015 Financial Results**

**Cash Position:** As of September 30, 2015 Collectis had €279.4 million in cash and cash equivalents compared to €112.3 million as of December 31, 2014. This increase is primarily attributable to the \$228 million of proceeds from Collectis' U.S. initial public offering in March 2015, partly offset by €22 million of cash flows used in operating activity, €3.3 million of acquisitions of tangible assets, and the repurchase for €3.5 million of 25% of the minority shares of Collectis Bioresearch S.A.S, in each case during the first nine months of 2015.

---

**Revenues and Other Income:** Total revenues and other income were €10.0 million for the third quarter of 2015 and primarily comprised €7.1 million of collaboration revenues, €0.5 million of license revenues, €1.0 million of grant revenues and €1.5 million of research tax credit revenues. Total revenues and other income were €27.2 million for the nine-month period ended September 30, 2015 and primarily comprised €21.7 million of collaboration revenues, €1.6 million of license revenues, €1.1 million of grant revenues and €2.8 million of research tax credit revenues.

**Total Operating Expenses and Other Operating Income:** Total operating expenses and other operating income for the third quarter of 2015 were €23.4 million, which includes non-cash stock-based compensation expenses of €9.5 million. Total operating expenses and other operating income for the nine-month period ended September 30, 2015 were €56.3 million, which includes non-cash stock-based compensation of €17.5 million.

**R&D Expenses:** Research and development expenses for the third quarter of 2015 were €13.5 million, including personnel expenses of €8.2 million and external purchases and other expenses of €5.3 million. Research and development expenses for the third quarter notably reflected the impacts of (i) non-cash stock-based compensation expense of €4.5 million and (ii) social charges related to stock-options granted during the third quarter of €1.8 million. Research and development expenses for the nine-months ended September 30, 2015 were €29.6 million, including personnel expenses of €19.2 million and external purchases and other expenses of €10.4 million. Research and development expenses for the nine-month period ended September 30, 2015 notably reflected the impacts of (i) non-cash stock-based compensation expense of €8.2 million and (ii) social charges related to free shares and stock-options granted during this period of €5.9 million.

**SG&A Expenses:** Selling, general and administrative expenses were €9.6 million for the third quarter of 2015, and included personnel expenses of €7.9 million and external purchases and other expenses of €1.7 million. SG&A expenses for the third quarter notably reflected the impacts of (i) non-cash stock-based compensation expense of €5.0 million and (ii) social charges related to stock-options granted during the third quarter of €1.8 million. Selling, general and administrative expenses were €25.9 million for the nine-month period ended September 30, 2015, and included personnel expenses of €19.1 million and external purchases and other expenses of €6.8 million. SG&A expenses for this nine-month period notably reflected the impacts of (i) non-cash stock-based compensation expense of €9.3 million and (ii) social charges related to free shares and stock-options granted during this period of €6.3 million.

**Financial Gain:** Financial gain was €0.7 million for the third quarter of 2015 and €0.5 million for the nine-month period ended September 30, 2015, which, in each case, is primarily attributable to an overall net favorable Euro-Dollar exchange rate applied to U.S. dollar-denominated cash and cash equivalents during the applicable periods.

**Net Loss Attributable to Shareholders of Collectis:** Net loss attributable to shareholders of Collectis was €12.8 million, or €0.36 per share, for the third quarter of 2015. This notably reflects the impact of (i) non-cash stock-based compensation of €9.5 million and (ii) social charges on stock-based compensation of €3.6 million. Adjusted net loss attributable to shareholders of Collectis for the third quarter of 2015, which excludes the non-cash stock-based compensation expense of €9.5 million, was €3.3 million, or €0.09 per share. Net loss attributable to shareholders of Collectis was €28.8 million or €0.85 per share, for the nine-month period ended September 30, 2015. This notably reflects the impact of (i) non-cash stock-based compensation of €17.5 million and (ii) social charges on stock-based compensation of €12.2 million. Adjusted net loss attributable to shareholders of Collectis for the nine-month period ended September 30, 2015, which excludes the non-cash stock-based compensation expense of €17.5 million, was €11.3 million, or €0.33 per share. Please see "Note Regarding Use of Non-GAAP Financial Measures" for a reconciliation of GAAP net income to adjusted net income.

---

## **Earnings Call Details**

Collectis will host an earnings call on November 17, 2015 at 8 am Eastern Time to discuss its financial results and provide a general business update.

### Dial-In Numbers:

Live PARTICIPANT Dial-In (Toll-Free US & Canada): 877-407-3104

Live PARTICIPANT Dial-In (International): +1 201-493-6792

### Replay Information:

Conference ID #: 13625168

Replay Dial-In (Toll Free US & Canada): 877-660-6853

Replay Dial-In (International): +1 201-612-7415

Expiration Date: 11/24/15

### Webcast URL (Archived for 12 months):

<http://collectis.equisolvewebcast.com/q3-2015>

---

STATEMENT OF CONSOLIDATED FINANCIAL POSITION  
(unaudited)  
(€ in thousands, except per share data)

	As of December 31, 2014	As of September 30, 2015
<b>ASSETS</b>		
<b>Non-current assets</b>		
Goodwill	-	-
Intangible assets	1 026	955
Property, plant, and equipment	2 610	4 884
Other non-current financial assets	1 977	492
<b>Total non-current assets</b>	<b>5 613</b>	<b>6 332</b>
<b>Current assets</b>		
Inventories and accumulated costs on orders in process	135	178
Trade receivables	5 881	1 682
Subsidies receivables	8 170	7 386
Other current assets	5 468	7 197
Cash and cash equivalents	112 347	279 356
<b>Total current assets</b>	<b>132 001</b>	<b>295 798</b>
<b>TOTAL ASSETS</b>	<b>137 614</b>	<b>302 129</b>
<b>LIABILITIES</b>		
<b>Shareholders' equity</b>		
Share capital	1 472	1 755
Premiums related to the share capital	192 842	405 943
Treasury share reserve	(251)	(340)
Currency translation adjustment	(762)	(2 124)
Retained earnings	(132 536)	(137 139)
Net income (loss)	20	(28 786)
<b>Total shareholders' equity - Group Share</b>	<b>60 786</b>	<b>239 309</b>
Non-controlling interests	(1 259)	262
<b>Total shareholders' equity</b>	<b>59 527</b>	<b>239 571</b>
<b>Non-current liabilities</b>		
Non-current financial debt	2 824	74
Non-current provisions	398	375
<b>Total non-current liabilities</b>	<b>3 222</b>	<b>449</b>
<b>Current liabilities</b>		
Current financial debt	862	2 981
Trade payables	9 802	6 665
Deferred revenues and deferred income	59 492	43 840
Redundancy plan	715	51
Current provisions	700	547
Other current liabilities	3 294	8 025
<b>Total current liabilities</b>	<b>74 865</b>	<b>62 110</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>137 614</b>	<b>302 129</b>

**STATEMENT OF CONSOLIDATED OPERATIONS**  
**3rd quarter of 2015 and first nine-months of 2015**  
(unaudited)  
(€ in thousands, except per share data)

	<b>For the three-month period ended September 30, 2015</b>	<b>For the nine-month period ended September 30, 2015</b>
<b>Revenues and other income</b>		
Revenues	7 600	23 356
Other income	2 379	3 845
<b>Total revenues and other income</b>	<b>9 978</b>	<b>27 201</b>
<b>Operating expenses and other operating income (expenses)</b>		
Royalty expenses	(334)	(1 153)
Research and development expenses	(13 476)	(29 641)
Selling, general and administrative expenses	(9 602)	(25 879)
Other operating income	0	515
Redundancy plan	24	259
Other operating expenses	(37)	(432)
<b>Total operating expenses and other operating income (expenses)</b>	<b>(23 425)</b>	<b>(56 331)</b>
<b>Operating loss</b>	<b>(13 447)</b>	<b>(29 130)</b>
<b>Financial gain (loss)</b>	<b>680</b>	<b>515</b>
Income tax	0	0
Income (loss) from continuing operations	(12 766)	(28 615)
Loss from discontinued operations	0	0
<b>Net loss</b>	<b>(12 766)</b>	<b>(28 615)</b>
Attributable to shareholders of Collectis	(12 766)	(28 786)
Attributable to non-controlling interests	0	171
<b>Basic earnings attributable to shareholders of Collectis per share (€/share)</b>	<b>(0.36)</b>	<b>(0.85)</b>

## Note Regarding Use of Non-GAAP Financial Measures

Collectis S.A. provides non-GAAP net income and non-GAAP net income per share measures that include adjustments to figures presented in accordance with GAAP. In presenting non-GAAP net income, GAAP net income is adjusted to exclude non-cash stock-based compensation expense. Collectis believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Collectis' financial performance. The non-GAAP financial measures used by Collectis may be calculated differently, and therefore may not be comparable to similarly titled non-GAAP financial measures used by other companies. Please refer below for a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

**RECONCILIATION OF GAAP TO NON-GAAP NET INCOME**  
3rd quarter of 2015 and first nine months of 2015  
(unaudited)  
(€ in thousands, except per share data)

	<b>For the three-month period ended September, 30 2015</b>	<b>For the nine-month period ended September 30, 2015</b>
<b>Net loss attributable to shareholders of Collectis</b>	(12 766)	(28 786)
Adjustment:		
Non-cash stock-based compensation expense	9 464	17 481
<b>Adjusted net loss attributable to shareholders of Collectis (€ in thousands)</b>	<b>(3 301)</b>	<b>(11 305)</b>
<b>Basic adjusted net loss attributable to shareholders of Collectis (€/share)</b>	<b>(0.09)</b>	<b>(0.33)</b>
<b>Weighted average number of outstanding shares, basic (units)</b>	<b>35 094 503</b>	<b>33 819 191</b>

## About Collectis

Collectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN<sup>®</sup> products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it.

TALEN<sup>®</sup> is a registered trademark owned by the Collectis Group.

## Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions and include, but are not limited to, statements regarding the outlook for Collectis' future business and financial performance. Forward-looking statements are based on management's current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances, many of which are beyond Collectis' control. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks. Collectis expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise.

## CONTACT:

### Collectis

### Media

Jennifer Moore, +1 917-580-1088

VP Communications

[media@collectis.com](mailto:media@collectis.com)

or

KCSA Strategic Communications

Caitlin Kasunich / Dixon Moretz

+1 212-896-1241 / +1 212-896-1251

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com) / [dmoretz@kcsa.com](mailto:dmoretz@kcsa.com)

or

### Investor relations contact

Simon Harnest, +1 646-385-9008

VP Finance and Investor Relations

[simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)